Cellular Biology |
From the Department of Molecular Cardiology (M.A.F., D.R.Z., R.W.D., M.B.), Department of Biostatistics and Epidemiology (C.A.-H.), and Center for Anesthesiology Research (D.S.D.), Cleveland Clinic Foundation, and Department of Physiology and Biophysics (D.R.Z., J.A.M., M.B.), School of Medicine, Case Western Reserve University, Cleveland, Ohio.
Correspondence to Meredith Bond, Department of Molecular Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. E-mail bondm{at}ccf.org
| Abstract |
|---|
|
|
|---|
Key Words: A-kinase anchoring proteins protein kinase A cardiac myocyte ß-adrenergic receptor contractility
| Introduction |
|---|
|
|
|---|
PKA holoenzyme contains 2 regulatory (R) and 2 catalytic (C) subunits. The 2 isoforms of PKA, types I and II, are distinguished by the R isoform. Most RII is targeted to specific subcellular sites by interaction with AKAPs.7 9 Targeting of RI by AKAPs has also been recently reported.10 Members of the AKAP family are functionally similar; they bind RII dimers and, by means of a targeting domain, anchor PKA II holoenzyme to specific subcellular locations. However, the subcellular targeting domain of each AKAP is unique; regions of similarity among AKAPs are restricted to domains of limited homology within the conserved amphipathic helix that binds RII dimers.11
More than 50 AKAPs have been identified in a number of
organisms.7 In particular, 2
AKAPs have been reported in the rat and human heart, mAKAP (formerly
AKAP100)12 and
AKAP18.13 The latter was
independently identified as AKAP15 in skeletal
muscle.14 RII and mAKAP
colocalize to the junctional SR (jSR)/transverse
tubule9 and the perinuclear
region.15 PKA is targeted by
mAKAP to the RyR and may be involved in PKA regulation of the
RyR.5 AKAP18 is a
lipid-anchored AKAP that is reported to be necessary for PKA-dependent
modulation of the skeletal and cardiac L-type
Ca2+ channel under ß-adrenergic
stimulation.13 14
AKAP15 also interacts directly with the
1
subunit of the skeletal calcium
channel.13
The goals of these studies were (1) to determine the physiological role of AKAP-mediated PKA anchoring in the regulation of cardiomyocyte contractility and (2) to identify protein substrates phosphorylated by anchored PKA in cardiac myocytes. We used the adenovirus gene transfer method16 to introduce Ht31, the RII-binding peptide derived from a human thyroid AKAP,17 18 into adult rat ventricular myocytes. Ht31 binds RII with the same nanomolar affinity as the full-length AKAP.17 19 Consequently, Ht31 peptide, which does not contain a targeting domain,18 competes with full-length AKAPs for binding of RII and PKA type II holoenzyme. Ht31P (a proline-substituted derivative), used as a negative control, contains 2 prolines substituted for 2 hydrophobic residues within the RII binding domain. This disrupts the secondary structure of the amphipathic helix necessary for RII binding and therefore does not block AKAP/RII interaction. We determined the effect of disruption of PKA targeting by endogenous AKAPs. This was achieved by assessing the effect of Ht31 expression in cardiac myocytes on PKA distribution, Ca2+ cycling, myocyte cell shortening, and PKA-dependent substrate phosphorylation.
| Materials and Methods |
|---|
|
|
|---|
Isolation, Culture, and Adenoviral Infection of
Cardiac Myocytes
Sprague-Dawley male rats (200 to 250 g) were
housed and cared for by the Cleveland Clinic Foundation Animal
Facility, which is approved by the American Association for
Accreditation of Laboratory Animal Care and is under the full-time
supervision of a veterinarian. All methods used are approved by the
Cleveland Clinic Foundation Animal Care and Use Committee and are
consistent with the recommendations of the American Veterinary Medical
Association.
Adult rat ventricular myocytes were isolated as previously described20 with modifications, as necessary, for primary culture of the cells.21 Myocytes were plated (1x105 rod-shaped cells per milliliter) on laminin (4 µg/cm2). Viability was routinely between 75% and 95% rod-shaped myocytes with no granulations or blebs. Adenovirus was diluted to 1x108 plaque-forming units per milliliter, and cells were infected for 1 hour.
Indirect Immunofluorescence
Myocytes were immunostained as
described.22 Anti-RII
antibody was diluted 1:100, and FITC-conjugated donkey anti-goat
secondary antibody was diluted 1:500. The cells were examined using a
Leica TCS-NT confocal laser scanning microscope with a x63 objective
lens as
described.9
Measurements of Intracellular
Ca2+ Transients and Myocyte Cell
Shortening
Simultaneous measurements of intracellular
Ca2+ and contraction were performed under
field stimulation (0.5 Hz) as
described.19 After a
4-minute equilibration period in Krebs-Henseleit buffer ([in mmol/L]
NaCl 118, KCl 4.8, MgCl2 1.2,
CaCl2 1.2,
KH2PO4 1.2,
NaHCO3 16.5, glucose 16.5, and pyruvate 7.5, and
50 U/mL penicillin and 50 µg/mL streptomycin, pH 7.35) (KHB) with no
agonist, the superfusate was switched to KHB containing 10 nmol/L
isoproterenol (Iso). Cell shortening and intracellular
Ca2+ were then measured for each cell under
baseline conditions (no agonist) and in the presence of Iso.
Dose-response experiments verified that 10 nmol/L Iso elicited a
maximal response in acutely isolated, uninfected adult rat ventricular
cardiomyocytes (data not shown).
For both the Ca2+ transient and cell shortening, the following parameters were measured: time to peak, time to 90% decline (T90r), change in amplitude from resting level, maximum rate of rise, and maximum rate of decline. Data for these parameters were collected for each cell (averaged over 10 contractions) after the amplitude of the cell shortening reached a steady state (3 to 5 minutes). Experiments were carried out under (1) field stimulation at 0.5 Hz with no agonist present (baseline) and (2) field stimulation in the presence of 10 nmol/L Iso (stimulated). Results were analyzed with Laboratory View software. Percentage cell shortening (%CS) was calculated as follows: (change in amplitude from resting cell length÷resting cell length)x100.
Statistical Analysis of
Ca2+ Cycling and Cell Shortening
Data
Before running any analyses, the
Ca2+ cycling and cell shortening data were
visually inspected to assess the assumption of normality. Because
logarithmically transformed data were distributed normally, analyses
were performed on the transformed data.
An ANOVA was used to test for group differences under baseline conditions. Hypothesis testing was conducted using a 2-sided alternative and a significance level of 0.01. The more stringent standard for significance was set because experiments were carried out on individual cells and the level of peptide expression in both groups varied from cell to cell, as determined by immunofluorescence. Because there were no statistically significant differences between the means of the Ht31P and uninfected groups, a control group was created by combining these 2 groups. The remainder of the analyses were conducted on the basis of a 2-group instead of a 3-group design.
An ANCOVA between groups (control versus Ht31-expressing cells), controlling for the baseline measurements (in the absence of Iso stimulation), was carried out to determine whether there was a difference between the means of the 2 groups in Ca2+ cycling and cell shortening parameters. A 2-sided alternative hypothesis and a significance level of 0.01 were used.
To test for differences within groups (ie, baseline versus stimulated), a paired Student t test was used. Note that because there is no contribution of between-group variability, smaller absolute differences can be found to be statistically significant by paired t test than by ANCOVA. This is evident in the differences in resting cell length within groups (-/+ Iso) versus between groups. The Statistical Analysis System (SAS) was used to generate data summaries and statistical tests.
Back-Phosphorylation
Back-phosphorylation experiments were carried out on
cultured myocytes as
described.19 Bands were
visualized using a StormImager and quantified using ImageQuant
software. Unlike the Ca2+ cycling and cell
shortening measurements, back-phosphorylation experiments were carried
out on populations of cells, and the data were normally distributed.
Therefore, comparisons between groups were made by 2-tailed Student
t test with a
P value <0.05 considered
significant.
| Results |
|---|
|
|
|---|
There was no difference in the percentage of rod-shaped cells between uninfected and infected cells under these conditions. Furthermore, there was no significant difference in RII distribution, intracellular Ca2+ cycling, cell shortening, or PKA substrate phosphorylation between uninfected and Ht31P-expressing myocytes either in the presence or absence of Iso. These results indicate that infection with recombinant adenovirus itself did not affect the parameters measured and that there were no discernible nonspecific peptide effects. Because statistical analysis showed no difference between Ht31P-expressing and uninfected cells in Ca2+ cycling or cell length parameters, all functional data were expressed as Ht31-expressing myocytes versus control (Ht31P-expressing cells+uninfected cells).
Distribution of RII in Ht31-Expressing and
Control Myocytes
We anticipated that expression of Ht31 in cardiac
myocytes would result in redistribution of RII from subcellular
locations, where the enzyme was targeted by endogenous AKAPs, to a more
diffuse cytosolic localization, whereas Ht31P expression would have no
discernible effect on RII distribution. In agreement with our previous
observations in freshly isolated rat ventricular
myocytes,9 RII localized to
the perinuclear region and to periodic transverse striations in
uninfected (data not shown) and Ht31P-expressing myocytes
(Figure 1A
). In contrast, in Ht31-expressing myocytes,
targeting of RII to the cross-striations or perinuclear area was
reduced to nondetectable levels. Instead, RII was located diffusely
throughout the cytosol
(Figure 1B
). Similar results were obtained by Lester et
al18 in a pancreatic cell
line expressing Ht31.
|
Effects of Ht31 on Intracellular
Ca2+ Transients and Cell Shortening
Figure 2
shows representative traces of
Ca2+ transients and cell shortening under
baseline and stimulated conditions for an uninfected and a
Ht31-expressing myocyte. Note that in both cells, as previously
reported,23 the resting
level of cytosolic Ca2+ increased and cell
length decreased on treatment with 10 nmol/L Iso. Consistent with the
expected effects of ß-adrenergic stimulation on
Ca2+ cycling and cell
shortening,1 2 3 4 5
in response to Iso stimulation, we observed a significant decrease in
T90r of the Ca2+ transient
(Figure 3A
) and significantly faster maximal rate of
Ca2+ reuptake
(Figure 3G
) in both groups of myocytes. There was also a
significant increase in amplitude of the
Ca2+ transient in control cells
(Figure 3C
). This increase is somewhat less than that
observed in freshly isolated
myocytes,24 most likely as a
result of changes in cultured myocytes such as a decreased T-tubule
network or adaptation to a 2-dimensional
environment.25 We also
observed a significantly faster maximal rate of
Ca2+ release
(Figure 3E
) in control myocytes. On Iso stimulation,
Ht31-expressing myocytes displayed a similar trend in these 2
parameters, but this did not achieve statistical significance. There
was also a significantly decreased T90r cell relengthening
(Figure 3B
), a significantly increased %CS
(Figure 3D
), significantly faster maximal rate of shortening
(Figure 3F
), and significantly faster maximal rate of
relaxation
(Figure 3H
) for both Ht31-expressing and control cells in
response to Iso. Resting cell length was also shorter with Iso
stimulation (control baseline, 103±3 µm; control stimulated, 100±3
µm; Ht31 baseline, 112±4 µm; and Ht31 stimulated, 110±4
µm).
|
|
The effect of inhibiting PKA anchoring on
Ca2+ cycling and cell shortening was then
investigated. None of the Ca2+ cycling or
cell shortening parameters differed significantly in cells expressing
Ht31 compared with control myocytes in the absence of Iso. The only
Ca2+ cycling parameter significantly
different between the 2 groups treated with 10 nmol/L Iso was T90r of
the Ca2+ transient, which was significantly
shorter in Ht31-expressing cells
(Figure 2A
). In contrast, several cell shortening parameters
were altered with Ht31 treatment. The increase in %CS
(Figure 3D
), faster rate of shortening
(Figure 3F
), and faster rate of relaxation
(Figure 3H
) in response to ß-adrenergic stimulation were
significantly greater in Ht31-expressing cells.
Phosphorylation of PKA Substrates in Ht31- and
Ht31P-Expressing Myocytes
Back-phosphorylation measures the extent of unfilled
PKA sites on protein substrates by back-phosphorylating empty
(unphosphorylated) sites with radiolabeled phosphate from
[
-32P]ATP.19
Therefore, the more a protein is phosphorylated by PKA in vivo, the
less radioactivity will be incorporated by back-phosphorylation,
resulting in less intense radioactive labeling of the
protein.
In all cells, activation of the ß-adrenergic pathway
resulted in significantly decreased back-phosphorylation of the PKA
substrates MBP-C, TnI, and PLB compared with baseline
(Figures 4A
through 4D), indicating increased in vivo
phosphorylation of these sites, in accordance with past
findings.1 2 3 4 5
Baseline and PKA-dependent phosphorylation of MBP-C, TnI, and PLB were
not significantly different between uninfected and Ht31P-expressing
myocytes; therefore, only Ht31- and Ht31P-expressing cells were
compared. However, in Ht31-expressing myocytes, in the presence of 10
nmol/L Iso, back-phosphorylation of MBP-C
(Figure 4B
) and TnI
(Figure 4C
) was significantly greater than in
Ht31P-expressing cells (15% and 33%, respectively), indicating a
significantly reduced PKA-dependent phosphorylation of TnI and MBP-C in
response to ß-adrenergic stimulation in Ht31-expressing cells. There
was no significant difference in baseline or PKA-dependent PLB
phosphorylation between Ht31- and Ht31P-expressing myocytes
(Figure 4D
). To determine whether the reduction of in vivo
phosphorylation of MBP-C and TnI in Ht31-expressing cells was due to a
reduction of PKA C subunit, Western blot analysis was carried out. We
found no difference in the level of C subunit between the 2 groups,
assuming control cells expressed C subunit at 100% (n=6) and
Ht31-expressing cells expressed C subunit at 102±2%
(n=4).
|
| Discussion |
|---|
|
|
|---|
This is the first study to examine the effect of blocking endogenous AKAP-PKA interactions on the phosphorylation of endogenous PKA substrates. We wished to determine the overall role of PKA anchoring in the regulation of cardiac contractility in isolated myocytes. This is a complex process because of the large number of PKA substrates in cardiac myocytes and the fact that the effects on contractility and relaxation in response to ß-adrenergic stimulation are due to the interplay of several phosphorylation events.
The increased amplitude of cell shortening observed in myocytes with disrupted PKA targeting could be attributed, at least in part, to the reduction of PKA phosphorylation of TnI. Phosphorylation of TnI decreases the sensitivity of the actomyosin ATPase to cytosolic Ca2+26 by decreasing the affinity of troponin C (TnC) for Ca2+.27 These findings are in agreement with a previous observation in transgenic mice expressing slow skeletal TnI that is not phosphorylated by PKA.26 In that study, a significant increase in the amplitude of cell shortening under stimulated conditions was observed. In addition, unphosphorylated MBP-C increased Ca2+ sensitivity in skinned fibers.28 Thus, in our experiments, the decreased PKA-dependent MBP-C phosphorylation may also have contributed to increased cell shortening in Ht31-expressing cells.
One might predict that increased myofibrillar Ca2+ sensitivity (due to decreased TnI and MBP-C phosphorylation) should lead to a longer relaxation time. However, we found that reduction of PKA-dependent TnI phosphorylation in Ht31-expressing myocytes was accompanied by a shorter relaxation time than in control cells. This apparent paradox may be explained in part by the results of Li et al,29 who recently showed that TnI phosphorylation did not participate in relaxation during unloaded shortening and that its contribution to accelerated relaxation during loaded shortening was minimal. Thus, the decrease of PKA-dependent TnI phosphorylation may have had little effect on the rate of relaxation in the unloaded myocytes used here. The reason for the shorter time of decline of the Ca2+ transient, accelerated rate of shortening, and accelerated rate of relaxation with loss of PKA anchoring during ß-adrenergic stimulation is unclear. These effects may be due to changes in phosphorylation of other-as-yet unidentified PKA substrates. There may also be functions for MBP-C that have not yet been described. Nevertheless, our findings indicate that inhibition of PKA anchoring in cardiac myocytes affects cell shortening with minimal alterations in Ca2+ cycling.
To date, the only studies investigating PKA compartmentalization in cardiac myocytes determined the effect of PKA targeting on L-type Ca2+ currents.14 30 31 These studies suggest that regulation of the L-type Ca2+ channel by PKA is dependent on AKAP/PKA interaction, specifically PKA targeting by AKAP18. In addition, localization of mAKAP at the jSR9 and association of mAKAP and RyR, as demonstrated by coimmunoprecipitation studies,5 suggests that mAKAP may regulate PKA phosphorylation of RyR and, thus, Ca2+-induced Ca2+ release. Because Ca2+ entering through the L-type Ca2+ channel and Ca2+-induced Ca2+ release from the RyR of the SR both contribute to the Ca2+ transient,3 32 we predicted that Ht31-expressing myocytes would display an altered Ca2+ transient under Iso-stimulated conditions as compared with control cells, most likely a reduced increase in amplitude.
The lack of significant difference in amplitude of the Ca2+ transient between Ht31-expressing and control cells under stimulated conditions suggests that the amount of Ca2+ entering the cytosol was not affected by loss of AKAP-mediated PKA anchoring. The lack of change in the Ca2+ transient in response to ß-adrenergic stimulation in Ht31 cells is unlikely due to a failure to detect changes in Ca2+, because we did observe an increase in the amplitude of the Ca2+ transient in both Ht31-expressing and control cells in response to Iso treatment. One possible explanation is an inability of expressed Ht31 peptide to compete with full-length endogenous AKAPs for RII. However, this is unlikely, because work from our laboratory33 shows that the affinity of Ht31 peptide for RII is 100-fold higher than AKAP18 and 10-fold higher than mAKAP. Overexpressed Ht31 is also likely to be present in the cardiac myocytes at much higher concentrations than endogenous AKAPs. Additionally, we have shown that periodicity of RII was lost in Ht31-expressing cells, thus verifying that Ht31 effectively competes with mAKAP for RII binding. Currently, we cannot rule out the possibility that in cultured adult cardiac myocytes, modulation of the L-type Ca2+ channel or RyR by targeted PKA is reduced.
PKA-dependent phosphorylation of at least 2 myofibrillar PKA substrates, TnI and MBP-C, was altered in Ht31-expressing myocytes. Consequently, our data are best explained by 1 of 2 models. The first involves an unidentified myofibril-associated AKAP that functions to sequester PKA near its major targets, TnI and MBP-C.34 35 Because a typical cell contains 5 to 10 distinct AKAPs (based on RII overlay assays),36 other AKAPs, in addition to the 2 identified to date, may be expressed in cardiac myocytes. Furthermore, microdomains or gradients of cAMP exist in response to adenylyl cyclase activation.8 In cells such as cardiac myocytes, with multiple PKA pools and PKA substrates, sequestering PKA to different subcellular locations would allow the pool closest to activated adenylyl cyclases to be stimulated most rapidly by the local high concentrations of cAMP after receptor activation. This pool of PKA could then phosphorylate nearby protein substrates. Intriguing results from the laboratory of Johnson and colleagues suggest that under certain conditions the C subunits may not even dissociate from the R subunits of PKA,37 thus strengthening the argument for the need to anchor PKA holoenzyme near its targets.
In the second model, PKA is not targeted to the myofilaments by AKAPs, but primarily near the jSR. Feliciello et al38 found enhanced phosphorylation of a distant PKA substrate, nuclear cAMP response element binding protein, by PKA targeted to the cytoskeleton near the plasma membrane via expressed AKAP75. By analogy, targeting of PKA by mAKAP at the jSR may facilitate a local increase in the concentration of activated C subunit. This increased local pool of C subunit could then diffuse to distant locations such as the myofilaments. It is possible that the most abundant PKA substrates, ie, TnI and MBP-C,34 35 would be most dependent on high concentrations of activated C subunit. Phosphorylation of these substrates would then be most affected by a decrease in the pool of activated PKA (near adenylyl cyclases), resulting from disruption of PKA targeting. Alternatively, it might be more difficult for the pool of activated C subunit to diffuse to myofibrils than to other subcellular locations. The microenvironment of the myofibrillar lattice, packed with thin and thick filaments and associated structural and regulatory proteins, may limit diffusion. If this is the case, then myofibrillar substrates may be more susceptible to a decrease in activated C subunit than PKA substrates located in more accessible subcellular locations.
Intriguingly, under the conditions of our experiments, myocytes that expressed Ht31 displayed enhanced contractility with no major change in the intracellular Ca2+ transient. Thus, the effect of Ht31 expression is similar to the action of Ca2+ sensitizing agents. These drugs, under study as promising treatments for heart failure, increase the sensitivity of myofilaments to intracellular Ca2+ without increasing the level of Ca2+.39 Ca2+ sensitizing agents either increase Ca2+ binding to TnC or act directly on the actin-myosin complex.39 Unfortunately, there are some drawbacks to several of these drugs, such as a high level of phosphodiesterase inhibition and impairment of relaxation.39 40 Our studies may suggest a new avenue of exploration for the treatment of heart failure. Ht31 expression has effects similar to advantages offered by Ca2+ sensitizing drugs, but not their drawbacks. For example, inhibition of AKAP/PKA interaction should not inhibit phosphodiesterase activity or impair relaxation.
In conclusion, AKAP-anchored PKA regulates contractility under conditions of ß-adrenergic stimulation in ventricular myocytes. This regulation occurs likely through phosphorylation of a subset of PKA substrates including MBP-C and TnI but not PLB. Much work is still needed to completely unveil the mechanisms of this regulation.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2. Kranias EG, Solaro RJ. Phosphorylation of troponin I and phospholamban during catecholamine stimulation of rabbit heart. Nature. 1982;298:182184.[Medline] [Order article via Infotrieve]
3. Brum G, Osterrieder W, Trautwein W. ß-Adrenergic increase in the calcium conductance of cardiac myocytes studied with the patch clamp. Pflugers Arch. 1984;401:111118.[Medline] [Order article via Infotrieve]
4. Garvey JL, Kranias EG, Solaro RJ. Phosphorylation of C-protein, troponin-I and phospholamban in isolated rabbit hearts. Biochem J. 1988;249:709714.[Medline] [Order article via Infotrieve]
5. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR. PKA phosphorylation dissociated FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365376.[Medline] [Order article via Infotrieve]
6. England PJ, Shahid M. Effects of forskolin on contractile responses and protein phosphorylation in the isolated perfused rat heart. Biochem J. 1987;246:687695.[Medline] [Order article via Infotrieve]
7. Colledge M, Scott JD. AKAPs: from structure to function. Trends Cell Biol. 1999;19:216221.
8. Cooper DMF, Mons N, Karpen JW. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature. 1995;374:421424.[Medline] [Order article via Infotrieve]
9.
Yang J, Drazba JA,
Ferguson DG, Bond M. A-kinase anchoring protein 100 (AKAP100) is
localized in multiple subcellular compartments in the adult rat heart.
J Cell Biol. 1998;142:511522.
10.
Huang LJS, Durick
K, Weiner JA, Chun J, Taylor SS. D-AKAP2, a novel protein kinase A
anchoring protein with a putative RGS domain.
Proc Natl Acad Sci
U S A. 1997;94:1118411189.
11.
Miki K, Eddy EM.
Single amino acids determine specificity of binding of protein kinase A
regulatory subunits by protein kinase A anchoring proteins.
J Biol Chem. 1999;274:2905729062.
12.
McCartney S,
Little BM, Langeberg LK, Scott JD. Cloning and characterization of
A-kinase anchor protein 100 (AKAP 100).
J Biol Chem. 1995;270:93279333.
13.
Gray PC, Tibbs
VC, Catterall WA, Murphy BJ. Identification of a 15-kDa cAMP-dependent
protein kinase-anchoring protein associated with skeletal muscle L-type
calcium channels. J Biol
Chem. 1997;272:62976302.
14. Fraser ID, Tavalin SJ, Lester LB, Langeberg LK, Westphal AM, Dean RA, Marrion NV, Scott JD. A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events. EMBO J. 1998;17:22612272.[Medline] [Order article via Infotrieve]
15. Kapiloff MS, Schillace RV, Westphal AM, Scott JD. MAKAP: an A-kinase anchoring protein targeted to the nuclear membrane of differentiated myocytes. J Cell Sci. 1999;112:27252736.[Abstract]
16. Hitt M, Bet AJ, Addison CL, Prevec L, Graham FL. Techniques for human adenovirus vector construction and characterization. In: Methods in Molecular Genetics. Vol. 7. Clifton, NJ: The Academic Press Inc; 1995:1330.
17.
Carr DW, Hausken
ZE, Fraser IDC, Stofko-Hahn RE, Scott JD. Association of the type II
cAMP-dependent protein kinase with a human thyroid RII-anchoring
protein. J Biol Chem. 1992;267:1337613382.
18. Lester LB, Langberg LK, Scott JD. Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. Proc Natl Acad Sci U S A. 1997;941494214947.
19.
Damron DS,
Summers BA. Arachidonic acid enhances contraction and intracellular
Ca2+ transients in individual rat
ventricular myocytes. Am J
Physiol. 1997;272:H350H359.
20. Westfall MV, Rust EM, Albayya F, Metzger JM. Adenovirus-mediated myofilament gene transfer into adult cardiac myocytes. Methods Cell Biol. 1998;52:307322.
21. Cambon N, Sussman MA. Isolation and preparation of single mouse cardiomyocytes for confocal microscopy. Methods Cell Sci. 1997;19:8390.
22.
Zakhary DR,
Moravec CS, Bond M. Regulation of PKA binding to AKAPs in the heart,
alterations in human heart failure.
Circulation. 2000;101:14591464.
23. Fujita S, Endoh M. Effects of endothelin-1 on [Ca2+]i-shortening trajectory and Ca2+ sensitivity in rabbit single ventricular cardiomyocytes loaded with indo-1/AM: comparison with the effects of phenylephrine and angiotension II. J Card Fail. 1996;2:S45S57.[Medline] [Order article via Infotrieve]
24.
Huang MH, Knight
PR, Izzo JL. Ca2+-induced
Ca2+ release involved in positive inotropic
effect mediated by cGRP in ventricular myocytes.
Am J Physiol. 1999;276:R259R264.
25.
Mitcheson JS,
Hancox JC, Levi AJ. Cultured adult cardiac myocytes: future
applications, culture methods, morphological and electrophysiological
properties. Cardiovasc Res. 1998;39:280300.
26.
Fentzke RC, Buck
SH, Patel JR, Lin H, Wolska BM, Stojanovic MO, Martin AF, Solaro J,
Moss RL, Leiden JM. Impaired cardiomyocyte relaxation and diastolic
function in transgenic mice expressing slow skeletal troponin I in the
heart. J Physiol. 1999;517:143157.
27. Solaro RJ, Moir AJ, Perry SV. Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart. Nature. 1976;262:615617.[Medline] [Order article via Infotrieve]
28.
Kunst G, Kress
KR, Gruen M, Uttenweiler D, Gautel M, Fink RHA. Myosin binding protein
C, a phosphorylation-dependent force regulator in muscle that controls
the attachment of myosin heads by its interaction with myosin S2.
Circ Res. 2000;86:5158.
29.
Li L, Desantiago
J, Chu G, Kranias EG, Bers DM. Phosphorylation of phospholamban and
troponin I in ß-adrenergic-induced acceleration of cardiac
relaxation. Am J Physiol. 2000;278:H769H779.
30. Gao T, Yatani A, DellAcqua ML, Sako H, Green SA, Dascal N, Scott JD, Hosey MM. cAMP-dependent regulation of cardiac L-type Ca2+ channels requires membrane targeting of PKA and phosphorylation of channel subunits. Neuron. 1997;19:185196.[Medline] [Order article via Infotrieve]
31. Gray PC, Johnson BD, Westenbroek RE, Hays LG, Yates JR, Scheuer T, Catterall WA, Murphy BJ. Primary structure and function of an A kinase anchoring protein associated with calcium channels. Neuron. 1998;20:10171026.[Medline] [Order article via Infotrieve]
32.
Niggli E, Lederer
WJ. Voltage-independent calcium release in heart muscle.
Science. 1990;250:565568.
33.
Zakhary DR, Fink
MA, Ruehr ML, Bond M. Selectivity and regulation of A-kinase anchoring
proteins in the heart: the role of autophosphorylation of the type II
regulatory subunit of cAMP-dependent protein kinase.
J Biol Chem. 2000;275:4138941395.
34. Sulakhe PV, Vo XT. Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Mol Cell Biochem. 1995;149/150:103126.
35.
Strang KT,
Sweitzer NK, Greaser ML, Moss RL. ß-Adrenergic receptor stimulation
increases unloaded shortening velocity of skinned single ventricular
myocytes from rats. Circ Res. 1994;74:542549.
36. Scott JD. Cytoskeletal regulation of membrane function: dissection of protein kinase and phosphatase targeting interactions. In: Society of General Physiologists Series. Vol 52. New York, NY: Raven Press; 1997:227239.
37. Yang S, Fletcher WH, Johnson DA. Regulation of cAMP-dependent protein kinase: enzyme activation without dissociation. Biochemistry. 1995;34:62676271.[Medline] [Order article via Infotrieve]
38. Feliciello A, Li Y, Avvedimento EV, Gottesman ME, Rubin CS. A-kinase anchor protein 75 increases the rate and magnitude of cAMP signaling to the nucleus. Curr Biol. 1997;7:10111014.[Medline] [Order article via Infotrieve]
39. Mathew L, Katz SD. Calcium sensitizing agents in heart failure. Drugs Aging. 1998;12:191204.[Medline] [Order article via Infotrieve]
40.
Mittmann C,
Eschenhagen T, Scholz H. Cellular and molecular aspects of contractile
dysfunction in heart failure. Cardiovasc
Res. 1998;39:267275.
This article has been cited by other articles:
![]() |
M. S. Kapiloff, L. A. Piggott, R. Sadana, J. Li, L. A. Heredia, E. Henson, R. Efendiev, and C. W. Dessauer An Adenylyl Cyclase-mAKAP{beta} Signaling Complex Regulates cAMP Levels in Cardiac Myocytes J. Biol. Chem., August 28, 2009; 284(35): 23540 - 23546. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. H. Mauban, M. O'Donnell, S. Warrier, S. Manni, and M. Bond AKAP-Scaffolding Proteins and Regulation of Cardiac Physiology Physiology, April 1, 2009; 24(2): 78 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Borbely, I. Falcao-Pires, L. van Heerebeek, N. Hamdani, I. Edes, C. Gavina, A. F. Leite-Moreira, J. G.F. Bronzwaer, Z. Papp, J. van der Velden, et al. Hypophosphorylation of the Stiff N2B Titin Isoform Raises Cardiomyocyte Resting Tension in Failing Human Myocardium Circ. Res., March 27, 2009; 104(6): 780 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Ryall, J. D. Schertzer, K. T. Murphy, A. M. Allen, and G. S. Lynch Chronic {beta}2-adrenoceptor stimulation impairs cardiac relaxation via reduced SR Ca2+-ATPase protein and activity Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2587 - H2595. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nie, C. B. McDonough, T. Huang, P. V. Nguyen, and T. Abel Genetic Disruption of Protein Kinase A Anchoring Reveals a Role for Compartmentalized Kinase Signaling in Theta-Burst Long-Term Potentiation and Spatial Memory J. Neurosci., September 19, 2007; 27(38): 10278 - 10288. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Gardner, A. P. Naren, and S. W. Bahouth Assembly of an SAP97-AKAP79-cAMP-dependent Protein Kinase Scaffold at the Type 1 PSD-95/DLG/ZO1 Motif of the Human beta1-Adrenergic Receptor Generates a Receptosome Involved in Receptor Recycling and Networking J. Biol. Chem., February 16, 2007; 282(7): 5085 - 5099. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Saucerman, J. Zhang, J. C. Martin, L. X. Peng, A. E. Stenbit, R. Y. Tsien, and A. D. McCulloch Systems analysis of PKA-mediated phosphorylation gradients in live cardiac myocytes PNAS, August 22, 2006; 103(34): 12923 - 12928. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Oti, B Snel, M A Huynen, and H G Brunner Predicting disease genes using protein-protein interactions J. Med. Genet., August 1, 2006; 43(8): 691 - 698. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Dodge-Kafka, L. Langeberg, and J. D. Scott Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of A-Kinase Anchoring Proteins Circ. Res., April 28, 2006; 98(8): 993 - 1001. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Casteel, G. R. Boss, and R. B. Pilz Identification of the Interface between cGMP-dependent Protein Kinase I{beta} and Its Interaction Partners TFII-I and IRAG Reveals a Common Interaction Motif J. Biol. Chem., November 18, 2005; 280(46): 38211 - 38218. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Takimoto, H. C. Champion, D. Belardi, J. Moslehi, M. Mongillo, E. Mergia, D. C. Montrose, T. Isoda, K. Aufiero, M. Zaccolo, et al. cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism Circ. Res., January 7, 2005; 96(1): 100 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. van der Velden, D. Merkus, B.R. Klarenbeek, A.T. James, N.M. Boontje, D.H.W. Dekkers, G.J.M. Stienen, J.M.J. Lamers, and D.J. Duncker Alterations in Myofilament Function Contribute to Left Ventricular Dysfunction in Pigs Early After Myocardial Infarction Circ. Res., November 26, 2004; 95(11): e85 - e95. [Abstract] [Full Text] |
||||
![]() |
P. Ping Identification of Novel Signaling Complexes by Functional Proteomics Circ. Res., October 3, 2003; 93(7): 595 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Jurevicius, V A. Skeberdis, and R. Fischmeister Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following {beta}2-adrenergic stimulation of ICa,L in frog ventricular myocytes J. Physiol., August 15, 2003; 551(1): 239 - 252. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. GEORGET, P. MATEO, G. VANDECASTEELE, L. LIPSKAIA, N. DEFER, J. HANOUNE, J. HOERTER, C. LUGNIER, and R. FISCHMEISTER Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8) FASEB J, August 1, 2003; 17(11): 1380 - 1391. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Ruehr, M. A. Russell, D. G. Ferguson, M. Bhat, J. Ma, D. S. Damron, J. D. Scott, and M. Bond Targeting of Protein Kinase A by Muscle A Kinase-anchoring Protein (mAKAP) Regulates Phosphorylation and Function of the Skeletal Muscle Ryanodine Receptor J. Biol. Chem., June 27, 2003; 278(27): 24831 - 24836. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. J Sichelschmidt, C. Hahnefeld, T. Hohlfeld, F. W Herberg, and K. Schror Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity Cardiovasc Res, June 1, 2003; 58(3): 602 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Alto, S. H. Soderling, N. Hoshi, L. K. Langeberg, R. Fayos, P. A. Jennings, and J. D. Scott Bioinformatic design of A-kinase anchoring protein-in silico: A potent and selective peptide antagonist of type II protein kinase A anchoring PNAS, April 15, 2003; 100(8): 4445 - 4450. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kammerer, L. L. Burns-Hamuro, Y. Ma, S. C. Hamon, J. M. Canaves, M. M. Shi, M. R. Nelson, C. F. Sing, C. R. Cantor, S. S. Taylor, et al. Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: A disease susceptibility polymorphism PNAS, April 1, 2003; 100(7): 4066 - 4071. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Houser and K. B. Margulies Is Depressed Myocyte Contractility Centrally Involved in Heart Failure? Circ. Res., March 7, 2003; 92(4): 350 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Affaitati, L. Cardone, T. de Cristofaro, A. Carlucci, M. D. Ginsberg, S. Varrone, M. E. Gottesman, E. V. Avvedimento, and A. Feliciello Essential Role of A-kinase Anchor Protein 121 for cAMP Signaling to Mitochondria J. Biol. Chem., January 31, 2003; 278(6): 4286 - 4294. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Dell'Acqua, K. L. Dodge, S. J. Tavalin, and J. D. Scott Mapping the Protein Phosphatase-2B Anchoring Site on AKAP79. BINDING AND INHIBITION OF PHOSPHATASE ACTIVITY ARE MEDIATED BY RESIDUES 315-360 J. Biol. Chem., December 6, 2002; 277(50): 48796 - 48802. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Altier, S. J. Dubel, C. Barrere, S. E. Jarvis, S. C. Stotz, R. L. Spaetgens, J. D. Scott, V. Cornet, M. De Waard, G. W. Zamponi, et al. Trafficking of L-type Calcium Channels Mediated by the Postsynaptic Scaffolding Protein AKAP79 J. Biol. Chem., September 6, 2002; 277(37): 33598 - 33603. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Kapiloff Contributions of Protein Kinase A Anchoring Proteins to Compartmentation of cAMP Signaling in the Heart Mol. Pharmacol., August 1, 2002; 62(2): 193 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Kapiloff, N. Jackson, and N. Airhart mAKAP and the ryanodine receptor are part of a multi-component signaling complex on the cardiomyocyte nuclear envelope J. Cell Sci., January 9, 2001; 114(17): 3167 - 3176. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Vila Petroff, J. M. Egan, X. Wang, and S. J. Sollott Glucagon-Like Peptide-1 Increases cAMP but Fails to Augment Contraction in Adult Rat Cardiac Myocytes Circ. Res., August 31, 2001; 89(5): 445 - 452. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |